LT2185B - 5'-dezoksi-5-fluorcitidino dariniu gavimo budas - Google Patents

5'-dezoksi-5-fluorcitidino dariniu gavimo budas

Info

Publication number
LT2185B
LT2185B LTRP802A LTRP802A LT2185B LT 2185 B LT2185 B LT 2185B LT RP802 A LTRP802 A LT RP802A LT RP802 A LTRP802 A LT RP802A LT 2185 B LT2185 B LT 2185B
Authority
LT
Lithuania
Prior art keywords
fluorcitidine
deoxy
daily receipt
receipt
daily
Prior art date
Application number
LTRP802A
Other languages
English (en)
Inventor
Morio Fujiu
Hideo Ishitsuka
Masanori Miwa
Isao Umeda
Kazzuteru Yokose
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of LT2185B publication Critical patent/LT2185B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
LTRP802A 1987-11-17 1993-07-20 5'-dezoksi-5-fluorcitidino dariniu gavimo budas LT2185B (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17
SU884356869A SU1736342A3 (ru) 1987-11-17 1988-11-16 Способ получени производных 5 @ -дезокси-5-фторцитидина

Publications (1)

Publication Number Publication Date
LT2185B true LT2185B (lt) 1993-10-15

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
LTRP802A LT2185B (lt) 1987-11-17 1993-07-20 5'-dezoksi-5-fluorcitidino dariniu gavimo budas

Country Status (35)

Country Link
US (1) US4966891A (lt)
EP (1) EP0316704B1 (lt)
JP (1) JPH0678350B2 (lt)
KR (1) KR970000241B1 (lt)
CN (1) CN1022688C (lt)
AR (1) AR247217A1 (lt)
AT (1) ATE124951T1 (lt)
AU (1) AU619220B2 (lt)
CA (1) CA1327358C (lt)
CS (1) CS274486B2 (lt)
DE (2) DE10199027I2 (lt)
DK (1) DK170893B1 (lt)
DZ (1) DZ1270A1 (lt)
ES (1) ES2074429T3 (lt)
FI (1) FI89804C (lt)
GR (1) GR3017686T3 (lt)
HK (1) HK1003114A1 (lt)
HU (1) HU199866B (lt)
IE (1) IE883430L (lt)
IL (1) IL88363A0 (lt)
IS (1) IS1895B (lt)
LT (1) LT2185B (lt)
LU (1) LU90769I2 (lt)
LV (1) LV5624A3 (lt)
MC (1) MC1992A1 (lt)
MX (1) MX173347B (lt)
NL (1) NL300045I2 (lt)
NO (2) NO171167C (lt)
NZ (1) NZ226923A (lt)
PH (1) PH25641A (lt)
PT (1) PT89009B (lt)
SU (1) SU1736342A3 (lt)
UA (1) UA19333A (lt)
YU (1) YU47122B (lt)
ZA (1) ZA888428B (lt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
TW254946B (lt) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1631278A4 (en) * 2003-05-20 2006-09-20 Aronex Pharmaceuticals Inc COMBINED CHEMOTHERAPY COMPRISING CAPECITABINE AND A COMPLEX BASED ON LIPOSOMIC PLATINUM
CA2550299C (en) * 2003-12-22 2010-03-30 Christopher R. Roberts Process for fluorocytidine derivatives
KR20070007104A (ko) * 2004-02-18 2007-01-12 아스트라제네카 아베 화합물
CA2554310A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Benzamide derivatives and their use as glucokinase activating agents
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
BRPI0516595A (pt) 2004-10-16 2008-09-23 Astrazeneca Ab processo para fabricar um composto, e, composto
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
JP2008534548A (ja) * 2005-04-01 2008-08-28 エフ．ホフマン−ラ ロシュ アーゲー カペシタビンの投与のための方法
WO2006125958A1 (en) * 2005-05-24 2006-11-30 Astrazeneca Ab 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
WO2007007040A1 (en) * 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP2301935A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
JP2009501734A (ja) * 2005-07-21 2009-01-22 ヌボ・リサーチ・インコーポレイテッド 癌の治療方法
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
AR064625A1 (es) 2006-12-21 2009-04-15 Astrazeneca Ab Forma cristalina de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
JP2010524960A (ja) * 2007-04-20 2010-07-22 ドクター・レディーズ・ラボラトリーズ・リミテッド カペシタビンを調製するためのプロセス
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20090122955A (ko) * 2008-01-03 2009-12-01 플러스 케미칼스, 에스.에이. 카페시타빈의 제조 방법
EP3443961B1 (en) 2008-06-17 2020-10-28 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
BRPI0916694B1 (pt) * 2008-08-04 2021-06-08 Wyeth Llc uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
CA2732165A1 (en) 2008-08-04 2010-02-11 Astrazeneca Ab Therapeutic agents 414
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
WO2010063080A1 (en) * 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
CA2755789C (en) 2009-04-06 2016-01-19 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
CN102858791A (zh) * 2009-07-23 2013-01-02 台湾神隆股份有限公司 制备氟胞苷衍生物的方法
RS54972B1 (sr) 2010-03-12 2016-11-30 Genzyme Corp Kombinovana terapija za lečenje raka dojke
JP2015518705A (ja) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
CA2881068C (en) * 2012-09-26 2021-06-08 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2014074725A1 (en) 2012-11-07 2014-05-15 Ohio State Innovation Foundation Substituted gemcitabine aryl amide analogs
CN105792830A (zh) * 2013-03-15 2016-07-20 Z·索 取代的吉西他滨双环酰胺类似物和使用其的治疗方法
EP3578663A1 (en) 2013-03-15 2019-12-11 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
CN109414438A (zh) * 2016-06-28 2019-03-01 塞尔利克斯生物私人有限公司 用于治疗癌症的组合物和方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3565549B1 (en) 2017-01-09 2022-03-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018200859A1 (en) 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
EP3817732A4 (en) * 2018-08-03 2022-06-08 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
JP2023535225A (ja) 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
TW202241931A (zh) 2021-01-08 2022-11-01 美商斯特蘭德治療股份有限公司 表現構築體及其用途
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
IS3412A7 (is) 1989-05-18
MX173347B (es) 1994-01-03
DZ1270A1 (fr) 2004-09-13
IL88363A0 (en) 1989-06-30
HU199866B (en) 1990-03-28
GR3017686T3 (en) 1996-01-31
MX13836A (es) 1993-10-01
PT89009B (pt) 1993-02-26
YU209188A (en) 1990-08-31
HK1003114A1 (en) 1998-10-09
NL300045I1 (nl) 2001-08-01
DK170893B1 (da) 1996-03-04
HUT48267A (en) 1989-05-29
IS1895B (is) 2003-10-20
FI885329A0 (fi) 1988-11-17
SU1736342A3 (ru) 1992-05-23
IE883430L (en) 1989-05-17
ZA888428B (en) 1989-06-28
AR247217A1 (es) 1994-11-30
AU619220B2 (en) 1992-01-23
NO171167B (no) 1992-10-26
CS274486B2 (en) 1991-04-11
YU47122B (sh) 1994-12-28
NO2001013I2 (no) 2006-05-01
PT89009A (pt) 1988-12-01
FI885329A (fi) 1989-05-18
DE10199027I1 (de) 2001-08-02
AU2516888A (en) 1989-05-25
EP0316704A2 (de) 1989-05-24
KR970000241B1 (ko) 1997-01-08
EP0316704A3 (en) 1990-11-22
PH25641A (en) 1991-08-21
LU90769I2 (fr) 2001-07-02
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
ATE124951T1 (de) 1995-07-15
DE3854148D1 (de) 1995-08-17
UA19333A (uk) 1997-12-25
JPH0678350B2 (ja) 1994-10-05
EP0316704B1 (de) 1995-07-12
NO171167C (no) 1993-02-03
NL300045I2 (nl) 2002-01-02
FI89804B (fi) 1993-08-13
NO885106L (no) 1989-05-18
JPH01153696A (ja) 1989-06-15
CS747588A2 (en) 1990-09-12
CN1033183A (zh) 1989-05-31
DE10199027I2 (de) 2002-01-31
US4966891A (en) 1990-10-30
DK640388A (da) 1989-05-18
ES2074429T3 (es) 1995-09-16
FI89804C (fi) 1993-11-25
NO885106D0 (no) 1988-11-16
CN1022688C (zh) 1993-11-10
DK640388D0 (da) 1988-11-16
NZ226923A (en) 1990-10-26
KR890008162A (ko) 1989-07-10
CA1327358C (en) 1994-03-01

Similar Documents

Publication Publication Date Title
LT2185B (lt) 5'-dezoksi-5-fluorcitidino dariniu gavimo budas
FI883596A (fi) Epipodofyllotoxinglukosid-4' -fosfatderivat.
DE68928739D1 (de) Detecteur d'humidite
ATA320788A (de) 5,5-dimethyl-3-phenylvinyl-1-aminoalkoxy-iminocyclohex-2-enderivate
FI885785A (fi) Epipodofyllotoxinglukosid-4'-acylderivat.
NO883857L (no) 3'-demetoksyepipodofyllotoksin-glukosidderivater.
IT9022047A0 (it) 13-desosso-4'-desossi-4'-iodoantracicline
IT1229579B (it) 10 norantracicline.
IT1226838B (it) Macinacaffe'.
IT207822Z2 (it) Contenitore 2000
SE8700965D0 (sv) "varmslaktemballering"
SE8704273D0 (sv) "kaffepasen"
SE8703558D0 (sv) "varmslaktemballering"
FR2650950B1 (fr) Capillo 47
IT8614903V0 (it) L'autotenda
AR241147A1 (es) "disposotivos taquimetricos"
IT8914502V0 (it) L'amicorario
BR8706415A (pt) Multiplexador-mdt 64
IT8828905V0 (it) Fifu' il porcellino handicappato
IT8819446V0 (it) Legapiu'
FI871839A0 (fi) Evighetsmaskin/2.
FI871840A0 (fi) Evighetsmaskin/2.
IT8732834V0 (it) Cup-dispenser 01.
IT8732835V0 (it) Cup-dispenser 02.
FI871841A0 (fi) Evighetsmaskin/3.

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20031116